Get the Stockscreener App
0.7251
3.96%
-0.0299
After Hours:
.75
0.0249
+3.43%
Invo Bioscience Inc stock is traded at $0.7251, with a volume of 106.53K.
It is down -3.96% in the last 24 hours and down -19.15% over the past month.
INVO Bioscience Inc operates a healthcare services fertility company. Assisted Reproductive Technology (ART) marketplace by making fertility care more accessible and inclusive to people. Its commercial strategy is focused on operating fertility-focused clinics, which includes the opening of dedicated INVO Centers offering the INVOcell and IVC procedure (with three centers in North America now operational) and the acquisition of US-based, profitable in vitro fertilization (IVF) clinics. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.
See More
Previous Close:
$0.755
Open:
$0.76
24h Volume:
106.53K
Relative Volume:
0.55
Market Cap:
$2.92M
Revenue:
$1.92M
Net Income/Loss:
$-8.81M
P/E Ratio:
-0.0457
EPS:
-15.86
Net Cash Flow:
$-5.41M
1W Performance:
-9.50%
1M Performance:
-19.15%
6M Performance:
-40.07%
1Y Performance:
-47.07%
1-Day Range:
$0.6812
$0.782
1-Week Range:
$0.6812
$0.826
52-Week Range:
$0.50
$3.50
Invo Bioscience Inc Stock (INVO) Company Profile
Name
Invo Bioscience Inc
Sector
Industry
Phone
(978) 878-9505
Address
5582 BROADCAST COURT, SARASOTA
Invo Bioscience Inc Stock (INVO) Latest News
Its Stock Has Paid Off Big Time For INVO Bioscience Inc - SETE News
Investor’s Delight: INVO Bioscience Inc (INVO) Closes Strong at 0.80, Up 2.72 - The Dwinnex
INVO Bioscience Inc (INVO)’s highs and lows: A closer look at its stock price fluctuations - US Post News
INVO (INVO Bioscience) Growth Rank : 1 (As of Aug. 18, 2024) - GuruFocus.com
INVO (INVO Bioscience) Long-Term Debt & Capital Lease Obligation : $4.35 Mil (As of Mar. 2024) - GuruFocus.com
INVO Stock Earnings: INVO Bioscience Reported Results for Q2 2024 - MSN
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA - StockTitan
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA - wallstreet:online
INVO Bioscience, Inc. (NASDAQ:INVO) Sees Large Growth in Short Interest - Defense World
INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Down 9.2% in July - Defense World
INVO’s Stock Market Adventure: -28.15% YTD Growth Amidst Volatility - The InvestChronicle
Artificial Insemination Kits Market Trends and Regional Analysis | Rinovum Women's Health LLC, INVO Bioscience ... - economica.ma
INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Update - Defense World
INVO Bioscience Enters Distribution Agreement for Taiwan - Quantisnow
Dr. Sue Ellen Carpenter of INVO Bioscience's Atlanta-based INVO CenterBloom FertilityNamed Top Doctor by ... - Quantisnow
INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM ... - Quantisnow
INVO Bioscience receives Nasdaq compliance extension By Investing.com - Investing.com
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX ... - Quantisnow
INVO Congratulates Wisconsin Fertility Institute on Being Named One of America's Best Fertility Clinics by Newsweek - Quantisnow
INVO Bioscience receives Nasdaq compliance extension - Investing.com
Artificial Insemination Kits Market Is Booming Worldwide – Rinovum Women's Health LLC, INVO Bioscience, MedGyn ... - TIMC
West Pharmaceutical Services (NYSE:WST) and INVO Bioscience (NASDAQ:INVO) Critical Comparison - Defense World
The Psychology of INVO Bioscience Inc Inc. (INVO) Price Performance: Understanding Market Sentiment - The InvestChronicle
Financial Snapshot: Analyzing INVO Bioscience Inc (INVO)'s Key Ratio Metrics – DWinneX - The Dwinnex
INVO Stock Earnings: INVO Bioscience Reported Results for Q1 2024 - MSN
INVO Reports Record First Quarter 2024 Financial Results - Investing.com India
INVO Reports Record First Quarter 2024 Financial Results - WICZ
INVO Bioscience Inc (INVO) Stock: A Year of Market Fluctuations - The InvestChronicle
Thinking about buying stock in Oncolytics Biotech, INVO Bioscience, Troika Media Group, Allarity Therapeutics, or ... - Marketscreener.com
INVO Bioscience (NASDAQ:INVO) Shares Down 7% - Defense World
I Make $200 a Day Gap Trading: So Can You - DataDrivenInvestor
Trading the Gap to Win in the Pre-Market - DataDrivenInvestor
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace
These Are the Top Reasons to Trade Penny Stocks in 2024 - PennyStocks
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid - Benzinga
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views - Benzinga
Healthcare Stocks in PlayINVO Bioscience (Nasdaq: INVO) Soars on Fourth Quarter and Full Year 2023 Financial ... - Investorideas.com newswire
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge - Benzinga
BestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences Merger - The Globe and Mail
INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market - The Globe and Mail
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings - Benzinga
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket - Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
INVO Stock Earnings: INVO Bioscience Reported Results for Q4 2023 - MSN
INVO Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire Inc.
INVO Stock Earnings: INVO Bioscience Reported Results for Q4 2023 - InvestorPlace
INVO Bioscience Seeks Funds After NAYA Misses Deadline - TipRanks
NAYA buys Florida Biotechnologies for $20M to get hold of rare genetic disease drug - Fierce Biotech
INVO Bioscience Files S-4 Registration and Preliminary - GlobeNewswire
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal - PR Newswire
Invo Bioscience Inc Stock (INVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):